Advertisement
At close: 04:00PM EST
After hours:
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 107.08 |
| Open | 107.00 |
| Bid | 105.20 x 900 |
| Ask | 107.25 x 800 |
| Day's Range | 106.97 - 107.86 |
| 52 Week Range | 68.53 - 107.86 |
| Volume | |
| Avg. Volume | 2,053,131 |
| Market Cap | 26.412B |
| Beta (5Y Monthly) | 0.77 |
| PE Ratio (TTM) | 175.67 |
| EPS (TTM) | 0.61 |
| Earnings Date | Jan 31, 2024 - Feb 05, 2024 |
| Forward Dividend & Yield | 2.00 (1.87%) |
| Ex-Dividend Date | Dec 29, 2023 |
| 1y Target Est | 108.75 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-13% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for CAH
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Cardinal Health, Inc.Analyst Report: Cardinal Health, Inc.Cardinal is one of the nation's largest pharmaceutical and medical distribution companies. Its Pharmaceutical segment distributes a wide range of branded and generic drugs, specialty drugs, and over-the-counter products. The Medical segment distributes medical, surgical, and laboratory products to hospitals and other healthcare providers. The company has about 44,000 employees. The shares are a component of the S&P 500.RatingFair ValueEconomic Moat5 days agoArgus Research
- Reuters
UPDATE 2-US FDA says BD recalling infusion pumps due to compatibility issues
The U.S. Food and Drug Administration (FDA) said on Friday that Becton Dickinson is recalling its Alaris infusion pumps due to compatibility issues with Cardinal Health's Monoject syringes. The health regulator said Alaris pumps are validated for use with Monoject syringes.
ZacksNevro's (NVRO) Latest Buyout to Boost SI Joint Pain Treatment
Nevro's (NVRO) latest acquisition is likely to bring long-term pain relief to people suffering from chronic low back pain associated with the SI joint.
Zacks5 Dividend Stocks Having Strong Growth Potential
Cboe Global (CBOE), Cardinal Health (CAH), Assurant (AIZ), Installed Building Products (IBP) and FedEx (FDX) have a strong dividend growth potential.
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.